One-Year Results of a Low-Profile Endograft in Acute, Complicated Type B Aortic Dissection.
Document Type
Article
Publication Date
9-27-2023
Publication Title
The Annals of thoracic surgery
Keywords
oregon; portland; cards; cards publication
Abstract
BACKGROUND: The safety and effectiveness of the RelayPro endograft (Terumo Aortic) was assessed for the treatment of acute, complicated type B aortic dissection (TBAD).
METHODS: A prospective pivotal trial analyzed a primary end point of all-cause mortality at 30 days. Secondary end points included technical success, major adverse events (disabling stroke, renal failure, and paraplegia/paralysis), endoleaks, patency, rupture, device integrity, false lumen perfusion, reinterventions, aortic expansion, and migration evaluated to 5 years.
RESULTS: The study involved 22 United States centers and enrolled 56 patients (mean age, 59.5 ± 11.4 years) from 2017 to 2021; of whom, 73.2% were men and 53.6% were African American. TBAD was complicated by malperfusion of the kidneys (51.8%), lower extremities (35.7%), and viscera (33.9%), and rupture (10.7%). Dissection extended proximally to zones 1/2 (14.3%) and zone 3 (78.6%) and distally to the iliac arteries (67.3%). Most procedures were percutaneous (85.5%). Technical success was 100%. Median hospitalization was 7 days (interquartile range, 5-12 days). All-cause mortality at 30 days was 1.8% (1 of 56; upper 95% CI, 8.2%; P < .0001). Seven major adverse events occurred in 6 patients (10.7%), consisting of paraplegia (n = 3), paraparesis (n = 2), disabling stroke (n = 1), and renal failure (n = 1). All paraplegia/paraparesis resolved with lumbar drainage. Kaplan-Meier analysis estimated a freedom from major adverse events of 89.1% at each interval from 30 days to 3 years. There was 1 endoleak (Type Ia), 2 retrograde dissections, and aortic diameter growth occurred in 2. There has been no rupture, fistula, component separation, patency loss, stenosis, kinking, twisting, bird beak, loss of device integrity, or fracture.
CONCLUSIONS: RelayPro is safe and effective in acute, complicated TBAD. Follow-up is ongoing to evaluate longer-term outcomes and durability.
Clinical Institute
Cardiovascular (Heart)
Department
Cardiology
Department
Surgery
Recommended Citation
Rossi, Peter J; Desai, Nimesh D; Malaisrie, S Chris; Lyden, Sean P; Nassiri, Naiem; Reece, T Brett; Adams, Joshua D; Moanie, Sina L; Shults, Christian C; RelayPro-D Investigators; and Ullery (RelayPro-D Investigators), Brant, "One-Year Results of a Low-Profile Endograft in Acute, Complicated Type B Aortic Dissection." (2023). Articles, Abstracts, and Reports. 7913.
https://digitalcommons.providence.org/publications/7913
